Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Apatinib + XELOX + RFA for Liver Metastases of Colorectal Cancer
NCT04202978Phase 2Unknown
- Sponsor
- Xiamen University Zhongshan Hospital
- Start
- Mar 2020
- Primary completion
- Mar 2021
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in colorectal cancer (CRC), sponsored by Xiamen University Zhongshan Hospital. Primary endpoint: R0 resection rate at 6 months. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04202978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04202978.